After completion of the current cohort 4, the data derived from...

After completion of the current cohort 4, the data derived from this trial will be used to inform our other CF33 clinical developments, and resources and finances from this study

will be re directed to our priority programs.

You'd have to ask what the deal was for Yuman to continue his trial seen as technically City of Hope is still responsible for it and I'd guess whatever information/data gets passed along to imugene after the trial is completed, as part of the deal.



If you discount B-Cell Immunotherapy and her-vaxx I guess that could be down to the 5 trials they are actually banking on, as these are not mentioned at all in the outlook for 2024.